Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4476820 | 0.96 | GPR119 (0.50) | FAAHGPR119HPGDKDM4EPKM | |
| SCHEMBL31747448 | 0.95 | GPR119 (0.51) | FAAHGPR119HPGDKDM4EPKM | |
| SCHEMBL5282029 | 0.94 | FAAH (0.48) | FAAHGPR119HPGDKDM4EPKM | |
| SCHEMBL1721300 | 0.92 | FAAH (0.47) | FAAHGPR119HPGDKDM4EPKM | |
| SCHEMBL26547589 | 0.90 | GPR119 (0.45) | FAAHGPR119HPGDKDM4EPKM | |
| SCHEMBL17104461 | 0.88 | GPR119 (0.54) | FAAHGPR119 | |
| SCHEMBL15373108 | 0.88 | NR1H2 (0.47) | FAAHGPR119HPGDKDM4EMEN1 | |
| SCHEMBL6794692 | 0.86 | FAAH (0.56) | FAAHGPR119HPGDKDM4EPKM | |
| SCHEMBL23006556 | 0.85 | ALDH1A1 (0.45) | FAAHGPR119HPGDKDM4EPKM | |
| SCHEMBL32687346 | 0.85 | ALDH1A1 (0.45) | FAAHGPR119HPGDKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES INC (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES INC (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2021252640-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-20090111778-A1 | 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| US-7468380-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-23 | — | — | US | disclosed |
| US-7468380-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-23 | — | — | US | disclosed |
| EP-1954137-A4 | 2-KETO-OXAZOLES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2008-12-17 | — | — | EP | disclosed |
| EP-1954137-A2 | 2-KETO-OXAZOLES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007061862-A2 | 2-KETO-OXAZOLES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-31 | — | — | WO | disclosed |
| US-20070004764-A1 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
| US-5340798-A | Platelet antiagglomerants | MERCK & CO., INC. (US) | 1994-08-23 | — | — | US | disclosed |
| US-5321034-A | Fibrinogen receptor antagonists | MERCK & CO., INC. (US) | 1994-06-14 | — | — | US | disclosed |
| WO-1994009029-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1994-04-28 | — | — | WO | disclosed |
| US-5281585-A | Secondary amide containing antagonist | MERCK & CO., INC. (US) | 1994-01-25 | — | — | US | disclosed |
| US-5264420-A | Anticoagulants | MERCK & CO., INC. (US) | 1993-11-23 | — | — | US | disclosed |
| WO-1992019595-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1992-11-12 | — | — | WO | disclosed |
| EP-0512831-A1 | Fibrinogen receptor antagonists | MERCK & CO. INC. (US) | 1992-11-11 | — | — | EP | disclosed |
| EP-0512829-A1 | Fibrinogen receptor antagonists | MERCK & CO. INC. (US) | 1992-11-11 | — | — | EP | disclosed |
| EP-0479481-A2 | Fibrinogen receptor antagonists | MERCK & CO. INC. (US) | 1992-04-08 | — | — | EP | disclosed |
| EP-0478362-A2 | Fibrinogen receptor antagonists | MERCK & CO. INC. (US) | 1992-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111778-A1 | 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase | FAAH, FAAH2, HCRTR2 | FAAH 1/4885GPR119 159/4885HPGD 794/4885 |
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | ASNS, SI, NARS1 | FAAH 3546/4885GPR119 1675/4885HPGD 340/4885 |
| US-20070004764-A1 | Nitrogen-containing aromatic derivatives | NR0B2, NR0B1, NR4A1 | FAAH 3105/4885GPR119 346/4885HPGD 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.